T20mg

Description

T20mg

T20mg: Research Dual Incretin Agonist (GLP-1 / GIP Pathways)
1× GLP-TIRZ (10mg)

Key Features

Dual-pathway incretin research peptide (GLP-1R + GIPR)
Lyophilized for stability and accurate laboratory handling
QC verified for identity and batch consistency

T20mg — Research Dual Incretin Agonist (GLP-1 / GIP)

T20mg is a mid-concentration dual incretin research peptide that simultaneously targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Furthermore, this balanced formulation makes it an ideal choice for researchers who require a moderate concentration for short-to-medium duration preclinical studies.

Research Focus (Non-Clinical)

Researchers actively deploy this compound to examine GLP-1R and GIPR dual-receptor activation pathways in metabolic research models. In addition, preclinical studies use it to investigate glucose homeostasis, insulin sensitivity markers, and energy expenditure endpoints at a mid-range concentration. Moreover, investigators study visceral adiposity reduction, lipid handling, and body composition changes under controlled laboratory conditions.

Product Specifications

Each vial contains 20mg of lyophilized T20mg, offering researchers a practical quantity for standard experimental protocols. Therefore, T20mg serves as the most versatile option between the 15mg and 40mg formulations. Additionally, NUPEPS Peptides verifies every batch for identity and purity through rigorous third-party lab testing.

Regulatory & Use

T20mg is strictly for laboratory research purposes only. It is not intended for human, veterinary, or diagnostic use. Qualified researchers can review the complete COA Library for batch-specific purity data.